Brian S Safina

List of Publications by Year
in descending order

32 papers	1,981 citations	304743 22 h-index	434195 31 g-index
32 all docs	32 docs citations	32 times ranked	2486 citing authors

#	Article	IF	Citations
1	A Non-covalent Ligand Reveals Biased Agonism of the TRPA1 Ion Channel. Neuron, 2021, 109, 273-284.e4.	8.1	52
2	A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment. Journal of Experimental Medicine, 2021, 218, .	8.5	56
3	Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy. Journal of Medicinal Chemistry, 2021, 64, 3843-3869.	6.4	22
4	Discovery of Acyl-sulfonamide Na_v1.7 Inhibitors GDC-0276 and GDC-0310. Journal of Medicinal Chemistry, 2021, 64, 2953-2966.	6.4	16
5	Antibodyâ€“Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. Bioconjugate Chemistry, 2019, 30, 1356-1370.	3.6	15
6	Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Na_v1.7 Inhibitors for the Treatment of Chronic Pain. Journal of Medicinal Chemistry, 2019, 62, 4091-4109.	6.4	21
7	TRPA1 modulation by piperidine carboxamides suggests an evolutionarily conserved binding site and gating mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26008-26019.	7.1	18
8	Identification of Selective Acyl Sulfonamideâ€“Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (Na_V) 1.7 with Potent Analgesic Activity. Journal of Medicinal Chemistry, 2019, 62, 908-927.	6.4	25
9	Discovery of a Potent (4R,5S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling. Journal of Medicinal Chemistry, 2018, 61, 3641-3659.	6.4	27
10	Discovery of Peptidomimetic Antibodyâ€“Drug Conjugate Linkers with Enhanced Protease Specificity. Journal of Medicinal Chemistry, 2018, 61, 989-1000.	6.4	63
11	Selective NaV1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain. Cell Reports, 2018, 24, 3133-3145.	6.4	49
12	Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3-a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNa_V1.7 Inhibitors for the Treatment of Pain. Journal of Medicinal Chemistry, 2018, 61, 4810-4831.	6.4	24
13	Design of Selective Benzoxazepin PI3KÎ´ Inhibitors Through Control of Dihedral Angles. ACS Medicinal Chemistry Letters, 2017, 8, 936-940.	2.8	21
14	Pyrrolobenzodiazepine Dimer Antibodyâ€“Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers. Journal of Medicinal Chemistry, 2017, 60, 9490-9507.	6.4	30
15	Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models. ACS Medicinal Chemistry Letters, 2016, 7, 277-282.	2.8	64
16	Structural Basis of Nav1.7 Inhibition by an Isoform-Selective Small Molecule Antagonist. Biophysical Journal, 2016, 110, 33a-34a.	0.5	0
17	Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist. Science, 2015, 350, aac5464.	12.6	261
18	Development of a Scalable Strategy for the Synthesis of PI3KÎ´ Inhibitors: Selective and Efficient Functionalization of Purine Derivatives. Organic Process Research and Development, 2013, 17, 138-144.	2.7	10

#	Article	IF	Citations
19	Identification of GNE-293, a potent and selective PI3KÎ´ inhibitor: Navigating in vitro genotoxicity while improving potency and selectivity. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4953-4959.	2.2	27
20	Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors. Journal of Medicinal Chemistry, 2012, 55, 8110-8127.	6.4	149
21	Potent and selective inhibitors of PI3KÎ´: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4296-4302.	2.2	48
22	Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta. Journal of Medicinal Chemistry, 2012, 55, 7686-7695.	6.4	56
23	Discovery of Novel PI3-Kinase Î´ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition. Journal of Medicinal Chemistry, 2012, 55, 5887-5900.	6.4	61
24	A Pentacyclic Aurora Kinase Inhibitor (AKI-001) with High in Vivo Potency and Oral Bioavailability. Journal of Medicinal Chemistry, 2008, 51, 4465-4475.	6.4	55
25	Combinatorial approach to identification of tyrphostin inhibitors of cytokine signaling. Bioorganic and Medicinal Chemistry, 2005, 13, 4269-4278.	3.0	8
26	A Mild and Selective Method for the Hydrolysis of Esters with Trimethyltin Hydroxide. Angewandte Chemie - International Edition, 2005, 44, 1378-1382.	13.8	331
27	Total Synthesis of Thiostrepton. Assembly of Key Building Blocks and Completion of the Synthesis. Journal of the American Chemical Society, 2005, 127, 11176-11183.	13.7	89
28	Total Synthesis of Thiostrepton. Retrosynthetic Analysis and Construction of Key Building Blocks. Journal of the American Chemical Society, 2005, 127, 11159-11175.	13.7	124
29	Total Synthesis of Thiostrepton, Part 1: Construction of the Dehydropiperidine/Thiazoline-Containing Macrocycle. Angewandte Chemie - International Edition, 2004, 43, 5087-5092.	13.8	95
30	Total Synthesis of Thiostrepton, Part 2: Construction of the Quinaldic Acid Macrocycle and Final Stages of the Synthesis. Angewandte Chemie - International Edition, 2004, 43, 5092-5097.	13.8	93
31	Synthetic Studies on Thiostrepton: Construction of Thiostrepton Analogues with the Thiazoline-Containing Macrocycle. Angewandte Chemie - International Edition, 2003, 42, 3418-3424.	13.8	63
32	A biomimetically inspired synthesis of the dehydropiperidine domain of thiostrepton. Angewandte Chemie - International Edition, 2002, 41, 1941-5.	13.8	8